Compare · GLP-1 agonist
Liraglutide vs Semaglutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Liraglutide | Semaglutide | |
|---|---|---|
| Evidence | 10/10 | 10/10 |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A once-daily GLP-1 drug with large RCT support for glucose control, weight loss, and lower cardiovascular risk in high-risk type 2 diabetes. | A GLP-1 drug with strong RCT evidence for weight loss, glucose control, and cutting cardiovascular events in high-risk patients. |
| Full profile → | Full profile → |
Liraglutide
Liraglutide is one of the most thoroughly studied metabolic drugs of the last fifteen years, and it's the direct predecessor to semaglutide. Its two approved uses rest on large, repeated, double-blind randomized trials (carefully controlled studies where neither patients nor doctors know who got…
Semaglutide
Semaglutide is one of the most heavily studied metabolic drugs of the past decade. Unlike most of the compounds we cover here, the human evidence is large, long-running, and consistent. So the honest job is simple: lay out where it holds up and where it doesn't.